Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S; Gruppo Oncologico dell’Italia Meridionale (GOIM). Orlando L, et al. Among authors: aieta m. Breast. 2024 Jun;75:103725. doi: 10.1016/j.breast.2024.103725. Epub 2024 Apr 5. Breast. 2024. PMID: 38615483 Free PMC article. Clinical Trial.
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, Quaranta A, Caliolo C, Ciccarese M, Cinefra M, Romito S, Pisconti S, Prete SD, Aieta M, Rizzi D, Maiello E, Colucci G, Cinieri S. Orlando L, et al. Among authors: aieta m. Breast. 2020 Oct;53:18-22. doi: 10.1016/j.breast.2020.06.002. Epub 2020 Jun 5. Breast. 2020. PMID: 32540553 Free PMC article. Clinical Trial.
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Maiello E, Di Maggio G, Cordio S, Cinieri S, Giuliani F, Pisconti S, Rinaldi A, Febbraro A, Latiano TP, Aieta M, Rossi A, Rizzi D, Di Maio M, Colucci G, Bordonaro R. Maiello E, et al. Among authors: aieta m. Clin Colorectal Cancer. 2020 Jun;19(2):109-115. doi: 10.1016/j.clcc.2020.01.003. Epub 2020 Jan 30. Clin Colorectal Cancer. 2020. PMID: 32089455 Free article. Clinical Trial.
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Ciccarese M, Orlando L, Fedele P, Schiavone P, Maiello E, Cilenti G, Aieta M, Bozza G, Forcignanò R, Febbraro A, Bordonaro R, Romito S, Rinaldi A, Borsellino N, Riccardi F, Pisconti S, Lorusso V, Colucci G, Surico G, Saracino V, Cinieri S; GOIM (Gruppo Oncologico dell’Italia Meridionale). Ciccarese M, et al. Among authors: aieta m. Breast J. 2020 Sep;26(9):1857-1859. doi: 10.1111/tbj.13856. Epub 2020 May 20. Breast J. 2020. PMID: 32436244 Clinical Trial. No abstract available.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM investigators. Ciardiello F, et al. Ann Oncol. 2016 Jun;27(6):1055-1061. doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002107 Free article. Clinical Trial.
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Martinelli E, et al. Among authors: aieta m. ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016. ESMO Open. 2017. PMID: 28848656 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
[High-dose chemotherapy of metastatic breast carcinoma].
Tartarone A, Aieta M, Morritti MG, Palomba G, Romano MP, Lelli G. Tartarone A, et al. Among authors: aieta m. Clin Ter. 1998 May-Jun;149(3):227-30. Clin Ter. 1998. PMID: 9842107 Review. Italian.
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Santini D, et al. Among authors: aieta m. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. PLoS One. 2014. PMID: 25170882 Free PMC article.
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G. Guida M, et al. Among authors: aieta m. BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2. BMC Cancer. 2018. PMID: 29747595 Free PMC article. Clinical Trial.
129 results